Abstract:Advanced smart microneedle arrays, incorporating platinum‐based nanozymes with a photothermal effect, enable precise drug release. The responsively released core–shell nanoparticles encapsulating stem cell secretome deactivate hepatic stellate cells, rejuvenate hepatocytes, and inhibit inflammation. Additionally, the released nanozymes proficiently deplete reactive oxygen species and alleviate hypoxia. This sophisticated approach integrating cell‐free therapy and nanocatalysis demonstrates significant efficacy in treating liver fibrosis. Liver fibrosis is a chronic pathological condition lacking specific clinical treatments. Stem cells, with notable potential in regenerative medicine, offer promise in treating liver fibrosis. However, stem cell therapy is hindered by potential immunological rejection, carcinogenesis risk, efficacy variation, and high cost. Stem cell secretome‐based cell‐free therapy offers potential solutions to address these challenges, but it is limited by low delivery efficiency and rapid clearance. Herein, an innovative approach for in situ implantation of smart microneedle (MN) arrays enabling precisely controlled delivery of multiple therapeutic agents directly into fibrotic liver tissues is developed. By integrating cell‐free and platinum‐based nanocatalytic combination therapy, the MN arrays can deactivate hepatic stellate cells. Moreover, they promote excessive extracellular matrix degradation by more than 75%, approaching normal levels. Additionally, the smart MN arrays can provide hepatocyte protection while reducing inflammation levels by ≈70–90%. They can also exhibit remarkable capability in scavenging almost 100% of reactive oxygen species and alleviating hypoxia. Ultimately, this treatment strategy can effectively restrain fibrosis progression. The comprehensive in vitro and in vivo experiments, supplemented by proteome and transcriptome analyses, substantiate the effectiveness of the approach in treating liver fibrosis, holding immense promise for clinical applications.

A New Strategy for Treatment of Liver Fibrosis

MiRNAs in liver fibrosis: new targets and opportunities for therapy

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

MicroRNA-101 Suppresses Liver Fibrosis by Downregulating PI3K/Akt/mTOR Signaling Pathway

Recent Progress in Understanding the Role of Micrornas in Hepatic Stellate Cell Biology and Liver Fibrosis Pathogenesis

MicroRNAs As Critical Regulators in Liver Fibrosis

MicroRNA targeted therapy in hepatitis

MicroRNAs in Liver Regeneration

MiRNA, a New Treatment Strategy for Pulmonary Fibrosis

Mir-345–5P Curbs Hepatic Stellate Cell Activation and Liver Fibrosis Progression by Suppressing Hypoxia-Inducible Factor-1Alpha Expression

Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis

Role of microRNAs in Hepatic Stellate Cells and Hepatic Fibrosis: An Update

MicroRNA-34a: A Novel Therapeutic Target in Fibrosis

Therapeutics Based on microRNA: A New Approach for Liver Cancer

MiR-22-3p and Mir-29A-3p Synergistically Inhibit Hepatic Stellate Cell Activation by Targeting AKT3

Smart Microneedle Arrays Integrating Cell‐Free Therapy and Nanocatalysis to Treat Liver Fibrosis

Role of Microrna in Liver Regeneration

Role of noncoding RNAs in liver fibrosis

Integrated Analysis of Hepatic Mirna and Mrna Expression Profiles in the Spontaneous Reversal Process of Liver Fibrosis.

Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy

Integration of high‑throughput data of microRNA and mRNA expression profiles reveals novel insights into the mechanism of liver fibrosis.